Skip to content
Open access

Molecular subgroups of ALS patients with distinct survival outcomes identified through plasma proteomics

Sep 2026 · medRxiv · 0 citations
Medicine

TL;DR

Cell-type enrichment analysis indicating a broad cellular origin of the circulating proteome, with contributions from nervous system cells, vascular cells, immune cells, and muscle cells, highlights the potential of plasma proteomics for clinically meaningful patient stratification in ALS.

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a phenotypically diverse neurodegenerative disorder characterized by the degeneration of motor neurons, ultimately resulting in loss of motor function. Currently, patients are classified based on clinical factors which does not fully capture the heterogeneity. Using the Olink Explore HT, we pro-filed ~5400 plasma proteins in ALS patients (n = 235) from the ALSrisc Study at Karolinska Institutet, Sweden, and applied consensus clustering, which revealed three patient subgroups significantly differing in survival outcome. Weighted gene correlation network analysis (WGCNA) and gene ontology (GO) analysis identified protein modules related to biological functions including cellular stress response and Rho-GTPase activity for the shorter surviving patient group. Cell-type enrichment analysis indicating a broad cellular origin of the circulating proteome, with contributions from nervous system cells, vascular cells, immune cells, and muscle cells. Our work highlights the potential of plasma proteomics for clinically meaningful patient stratification in ALS.

Read PDF

Similar papers

Open access Aug 2026

Characterizing shared and distinctive molecular phenotypes across motor regions in ALS with and without TDP-43 pathology in a veteran cohort

These findings identify senescence-associated molecular states within vulnerable neuronal populations in ALS and support a model in which persistent stress adaptation may permit neuronal survival while contributing to progressive cellular dysfunction.

P. H. Doyle, Shiva Kazempour Dehkordi, Timothy C. Orr et al. · 0 citations
Open access Sep 2026

Plasma immune signatures associate with neurodegeneration in frontotemporal lobar degeneration

Plasma multiplex proteomics identified complementary dimensions of neuroaxonal injury and immune dysregulation across frontotemporal lobar degeneration-related syndromes and candidates for independent biomarker validation and mechanistic investigation are identified.

M. van Schaik, K. O. Lai, N. Shapiro et al. · 0 citations
Open access Sep 2026

Circulating extracellular vesicle lipidomics identifies distinct signatures of amyotrophic lateral sclerosis and spinal muscular atrophy

Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disorder lacking established biomarkers of underlying disease biology. Here, we identify lipidomic signatures of circulating extracellular vesicles (EVs) that distinguish ALS from neurologically healthy controls and related neuromuscular diseases....

V. Ricotti, A. Fogel, M. van den Bosch et al. · 0 citations
Open access Sep 2026

Lysosomal Expression Profile in Plasma Associates with Disease Severity in Parkinson's Disease.

These findings support the use of pathway-specific biomarkers for improving PD diagnostics and monitoring disease progression and support the use of pathway-specific biomarkers for improving PD diagnostics and monitoring disease progression.

Janna van Wetering, M. V. van Ingen, Evelien Timmermans et al. · 0 citations
Open access Sep 2026

Integrating Single-Molecule Variant Phenotyping with Clinical Features Predicts Outcomes in KIF1A-Associated Neurological Disorder

Using KIF1A-associated neurological disorder (KAND) as a model system, single-molecule biophysical phenotyping of 91 pathogenic variants with longitudinal clinical characterization of 343 patients offers a prognostic tool and a stratification strategy for clinical trials.

Lu Rao, Wen-Xing Li, Jessica Waxler et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.